Explore ways to invest in OpenEvidence stock before, during, and after a future IPO—covering pre-IPO access, broker participation, valuation risks, and what retail investors should realistically expect.
Abridge’s rapid growth and strong clinical ties position it as a standout in healthcare AI, but limited share access and high valuations mean investors should track its progress carefully ahead of any future IPO.
WHOOP is a wearable device company with powerful technology to monitor athletes’ performance. Accredited investors may have an opportunity to own shares in this private company before the IPO. Read on to learn how to buy WHOOP stock. Availability may be limited.
Strava IPO buzz is building. Learn how to invest in Strava stock before it goes public, explore pre-IPO platforms, and see which brokers may offer access when shares hit the market.
Ro is reshaping digital healthcare with a tech-first model. From erectile dysfunction to chronic care, it’s expanding fast—investors should watch for the S-1 to assess growth, margins, and long-term potential.
Medline’s IPO is in motion, with private equity firms aiming for a $50B valuation. Strong fundamentals and a massive potential exit make this one of the most anticipated healthcare offerings this year.
Hinge Health leads in digital MSK care, using AI, virtual therapy, and wearables. An upcoming IPO may offer investors access, but valuations have dipped. Long-term success depends on scaling, competition, and employer adoption. Patience is key for investors.
The Oura Ring is revolutionizing wearable tech with its sleek design and focus on sleep health. Backed by $550M in funding and a $5.2B valuation as of January 2025, Oura eyes future growth in biometrics like glucose monitoring while considering its public future.
Neuralink is Elon Musk’s attempt to bridge the gap between the digital world and the human brain. The medical applications of a brain-machine interface could improve the lives of millions. Though Musk’s ultimate goal is to merge AI and I.
eGenesis has developed a gene editing process to make pig organs transplantable into humans. CRISPR has the potential to reduce immune reject, thus creating a long-term solution to the global organ donor shortage.
Thanks to its wealthy founder, Neuralink gets most of the brain-computer interface (BCI) news coverage. But an Australian/U.S.-based company is further along the FDA approval process, and its device is less intrusive than its competitors.
Finland-based Amer Sports is owned by a consortium of international investors looking to IPO the company in 2024. Popular Amer Sports brands include Wilson Sporting Goods, Atomic, Salomon, and Arc’teryx.